Updated review of Janus kinase inhibitors for the management of inflammatory bowel disease

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 1

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Pharmacol Ther. Mar 5, 2026; 17(1): 112788
Published online Mar 5, 2026. doi: 10.4292/wjgpt.v17.i1.112788

Table 7 Newer Janus kinase inhibitors

JAK: Janus kinase; UC: Ulcerative colitis; CD: Crohn’s disease; TYK: Tyrosine kinase; IBD: Inflammatory bowel disease.

Citation: Malakar S, Giri S, Jena A, Nath P. Updated review of Janus kinase inhibitors for the management of inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2026; 17(1): 112788
URL: https://www.wjgnet.com/2150-5349/full/v17/i1/112788.htm
DOI: https://dx.doi.org/10.4292/wjgpt.v17.i1.112788

Malakar S, Giri S, Jena A, Nath P. Updated review of Janus kinase inhibitors for the management of inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2026; 17(1): 112788 [PMID: 41809214 DOI: 10.4292/wjgpt.v17.i1.112788]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.